Drug Trial Radar · NCT06350006
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
924
Planned (sponsor's estimate)
Start
May 29, 2024
Primary completion
Dec 30, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study. Phase III: A randomized, Open-Label, multicenter clinical study of SHR-A1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors.
Conditions
- CLDN18.2-positive Advanced Solid Tumor
Interventions
SHR-A1904; AdebrelimabDrug
SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
SHR-A1904; CAPOX; AdebrelimabDrug
SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of AETime frame: Up to follow-up period, approximately 24 months
- Dose Limiting Toxicity (DLT)Time frame: approximately 24 months
- Maximal Tolerable Dose (MTD)Time frame: approximately 24 months
- Phase III Recommended Dose (RP3D)Time frame: approximately 24 months
- Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteriaTime frame: approximately 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.